UK Proton Pump Inhibitor, Statin Rx Restrictions Open For Comment
This article was originally published in The Tan Sheet
Executive Summary
The Royal Pharmaceutical Society of Great Britain is proposing drugs indicated for gastroesophageal reflux disease, hypercholesterolemia and hypertension among the list of therapies to be considered for potential non-Rx sale
You may also be interested in...
Three-Month Marketing Exclusivity Proposed For UK First-In-Class Switches
A drug sponsor that is the first to successfully switch an ingredient from Rx to nonprescription status in the UK would receive 90 days of marketing exclusivity under a Medicines Control Agency proposal
Third Class Of Drugs Should Not Be “Completely Closed Down” – Ganley
Debate on the merits of a third class of drugs could resurface as FDA considers Rx-to-OTC switch applications of drugs indicated for chronic conditions
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC